Actively Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Led by Treeline Biosciences, Inc. · Updated on 2026-03-27
180
Participants Needed
12
Research Sites
279 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
CONDITIONS
Official Title
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have measurable disease at study entry
- Diagnosed with one of the following hematologic malignancies: Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL) grade 3b or transformed from FL after at least 2 prior therapies
- FL grade 1-3a requiring treatment after at least 2 prior therapies
- Peripheral T-cell lymphoma (PTCL) subtypes relapsed or refractory after at least 1 prior systemic treatment, including angioimmunoblastic and follicular helper T-cell lymphoma types
- High-Grade B-Cell Lymphoma relapsed or refractory after at least 2 prior systemic treatments
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- Current central nervous system (CNS) involvement of lymphoma
- CNS lymphoma history must be fully treated with no recurrence in past 12 months
- Autologous stem cell transplantation within 60 days prior to study start
- Allogeneic stem cell transplantation within 90 days prior to study start
- CAR T-cell or other T-cell targeting treatment within 4 weeks prior to study start
- Major surgery or severe trauma within 4 weeks prior to study start
- Any significant acute or chronic illness, active or uncontrolled infection, or lab abnormalities posing unacceptable risk
- Pregnant or breastfeeding
- Conditions that could affect drug absorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Stanford Medicine Cancer Center
Palo Alto, California, United States, 94304
Actively Recruiting
2
The START Center for Cancer Care - Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
Washington University School of Medicine
St Louis, Missouri, United States, 63108
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
5
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
6
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
7
Macquarie University Hospital
Macquarie Park, New South Wales, Australia, 2113
Actively Recruiting
8
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Actively Recruiting
9
Cabrini Health
Malvern, Victoria, Australia, 3144
Actively Recruiting
10
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Actively Recruiting
11
Linear Clinical Research
Perth, Western Australia, Australia, 6009
Actively Recruiting
12
BC Cancer - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
Research Team
T
Treeline Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here